1832sek
-1,0 %
Date:2026-06-18Time:18:00:00Latest report:Q1-2026List:First NorthTicker:GENO
Market Cap:1 236 msekEnterprise Value:1 136 msekNet Sales:130,2 msekEarnings:24,3 msekEmployees:0ISIN:SE0002485979

Ratios

10-year key figure history for Genovis turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Genovis with index and moving average MA50 and MA200.

Stockprice:18,32
MA50:19,87
MA200:20,41
Price/MA200:-10,2 %
RSI (14):37,7
Price/MA50:-7,8 %

Description

Genovis delivers biotechnology tools and technology platforms to the life sciences and pharmaceutical industries. The company develops enzyme and inhibitor technologies that facilitate, or are integral parts of, a wide range of processes from basic research to pharmaceutical manufacturing and diagnostics. The company operates on a global scale, with customers primarily in North America, Europe and East Asia. Genovis was founded in 1999 and is headquartered in Kävlinge.

Biotechnology